Company Profile

Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient's autologous HSCs into a gene-modified cellular drug product to treat the patient's disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).

Employees

Sector

Pharmaceuticals

More about the company

Apr. 30	Orchard Therapeutics Awarded Innovation Passport Designation for Otl-201 in Mps-Iiia	CI
25-07-07	Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of Otl-203 for Mps-I Hurler Syndrome	CI
25-05-13	Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-Term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025	CI
25-02-12	Orchard Therapeutics Announces the Appointment of Robin Kenselaar as Chief Commercial Officer	CI
24-03-18	Orchard Therapeutics Receives FDA Approval of Lenmeldy? (atidarsagene autotemcel)	CI
24-02-05	Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome	CI
24-01-26	Japanese Shares Skid as Inflation Slows Faster-than-Expected in January	MT
24-01-25	Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics	MT
24-01-24	Orchard Therapeutics plc Announces Board Changes	CI
24-01-24	Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin	MT
24-01-24	Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index	CI
24-01-23	Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.	CI
23-12-11	Orchard Therapeutics’ Gene Therapy Gets Swiss Regulatory Approval	MT

23-10-05	Cantor Fitzgerald Downgrades Orchard Therapeutics to Neutral From Overweight, Raises Price Target to $16 From $15	MT
23-10-05	Stifel Downgrades Orchard Therapeutics to Hold From Buy, Cuts Price Target to $16 From $22	MT
23-06-13	Oppenheimer Adjusts Orchard Therapeutics Price Target to $34 From $37, Maintains Outperform Rating	MT
23-03-28	Cantor Fitzgerald Adjusts Orchard Therapeutics' Price Target to $15 From $3, Keeps Overweight Rating	MT
23-03-13	Oppenheimer Adjusts Orchard Therapeutics Price Target to $37 From $5, Maintains Outperform Rating	MT

24-05-07	Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024	AQ
24-05-06	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	AQ
24-05-03	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	AQ
24-04-03	FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy	AQ
24-03-20	FDA approves innovative gene therapy for MLD	AQ

23-10-05	Wall Street terughoudend richting banenrapport
23-10-05	Wall Street koerst lager
23-10-05	Japans bedrijf neemt Orchard Therapeutics over
21-08-05	Pharming blijft positief
21-07-01	AEX overtuigend hoger

Manager	Title	Age	Since
Bobby Gaspar CEO	Chief Executive Officer	62	2020-03-17
Frank Thomas PSD	President	56	2020-03-17
Fulvio Mavilio CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31

ORCHAR Stock Nasdaq

Stocks

US68570P1012

Pharmaceuticals

Latest news : ORCHAR

Analysts' recommendations : ORCHAR

Press Releases : ORCHAR

News in other languages : ORCHAR

Managers and Directors : ORCHAR

Other Pharmaceuticals

Company Profile

Director	Title	Age	Since
Takeyoshi Yamashita BRD	Director/Board Member	64	2024-01-23
Yasuo Fujii BRD	Director/Board Member	-	2024-01-23
Abdul Mullick BRD	Director/Board Member	-	2024-01-23

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORCHAR	-.--%	-.--%	-	-	380M
ELI LILLY AND COMPANY	-1.45%	-2.65%	+53.92%	+104.86%	1,034B
JOHNSON & JOHNSON	-1.05%	+2.93%	+54.34%	+71.71%	671B
ABBVIE INC.	-1.29%	+0.40%	+20.42%	+75.56%	460B
ROCHE HOLDING AG	-0.21%	-0.72%	+29.16%	+38.21%	353B
NOVARTIS AG	-1.25%	+4.80%	+24.79%	+45.66%	309B
ASTRAZENECA PLC	-1.28%	+0.42%	-1.38%	+12.44%	255B
AMGEN INC.	-1.59%	+1.35%	+56.46%	+72.53%	240B
NOVO NORDISK A/S	-0.76%	+1.22%	-17.03%	-54.36%	207B
GILEAD SCIENCES, INC.	-0.85%	+3.22%	+33.34%	+100.07%	188B
Average	-0.94%	+1.27%	+28.22%	+51.85%	412.97B
Weighted average by Cap.	-1.12%	+1.04%	+36.45%	+66.43%